VRDN — Viridian Therapeutics, Inc. stock price, charts and financials

QT65Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
23.05
-0.54-2.29%
OverviewShort InterestFilings
VRDNQT65Viridian Therapeutics, Inc.·NASDAQ
23.05-2.29%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ABCL+31.03%$9.08STOK-1.46%$32.23TSHA-0.69%$6.51GHRS-2.07%$29.64RAPP+1.31%$46.09NKTR-1.75%$75.14ZBIO-1.46%$31.96MESO+4.96%$16.73
Snapshot
Index-P/E-EPS (ttm)-17.07Insider Own31.88%Shs Outstand90.00MPerf Week24.68%
Market Cap2.12BForward P/E-EPS next Y-2.54Insider Trans4.10%Shs Float73.78MPerf Month16.78%
Enterprise Value2.20BPEG-EPS next Q-Inst Own-Short Float25.65%Perf Quarter38.76%
Income-322.91MP/S29.85EPS this Y77.44%Inst Trans-Short Ratio7.55Perf Half Y-19.13%
Sales71.13MP/B3.84EPS next Y33.94%ROA-35.27%Short Interest18.92MPerf YTD-24.20%
Book/sh-P/C-EPS next 5Y-ROE-61.35%52W High33.50 -31.20%Perf Year37.15%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-39.21%52W Low12.88 78.98%Perf 3Y28.49%
Dividend Est.-EV/EBITDA-Sales past 3/5Y228.66% 134.56%Gross Margin99.38%Volatility6.06% 4.61%Perf 5Y51.90%
Dividend TTM-EV/Sales30.93EPS Y/Y TTM16.58%Oper. Margin-569.68%ATR (14)0.99Perf 10Y-79.84%
Dividend Ex-Date-Quick Ratio16.95Sales Y/Y TTM-Profit Margin-544.06%RSI (14)76.06Recom2.13
Dividend Gr. 3/5Y-Current Ratio16.95EPS Q/Q-3.45%SMA2019.79%Beta0.96Target Price37.25
Payout0.00%Debt/Eq0.37Sales Q/Q-SMA5028.46%Rel Volume0.79Prev Close23.59
Employees252LT Debt/Eq0.07EarningsNov 16SMA200-1.53%Avg Volume2.11MPrice23.05
IPO DateJun 18, 2014Option/ShortYes / YesEPS/Sales Surpr.16.74% 290.77%Net Debt/EBITDA-0.21Volume1,659,799Change-2.29%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedTruist FinancialBuy$38 → $39
Aug-07-26ReiteratedRBC CapitalOutperform$35 → $36
Jun-30-26ReiteratedGoldman SachsBuy$35 → $39
Jun-30-26ReiteratedTruist SecuritiesBuy$35 → $38
Jun-29-26ReiteratedTruist FinancialBuy$33 → $35
Jun-29-26UpgradeWells FargoEqual Weight → Overweight$31
May-15-26ReiteratedEvercore ISI GroupOutperform$45 → $26
May-13-26ReiteratedStifel Nicolaus$48 → $39
May-06-26ReiteratedRBC CapitalOutperform$45 → $34
Apr-21-26ReiteratedTruist SecuritiesBuy$36 → $33
Latest News
Aug-07-26
Aug-07-2609:27AM
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39Benzinga
Aug-06-26
Aug-06-2603:02PM
Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pendingglobenewswire.com
08:00AM
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Resultsgurufocus.com
Aug-03-26
Aug-03-2604:16AM
Viridian Therapeutics (NASDAQ:VRDN) and Zai Lab (NASDAQ:ZLAB) Financial Reviewdefenseworld.net
Jul-01-26
Jul-01-2606:21AM
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - SlideshowSeekingAlpha
Jun-30-26
Jun-30-2608:30AM
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approvalseekingalpha.com
Jun-29-26
Jun-29-2602:12PM
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcriptseekingalpha.com
09:24AM
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Diseasebenzinga.com
Jun-26-26
Jun-26-2606:03PM
Viridian Therapeutics Receives FDA Approval For Lumvoa For The Treatment Of Thyroid Eye Disease; Co. Plans To Launch Lumvoa ImmediatelyBenzinga
Jun-25-26
Jun-25-2601:23AM
Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market AppreciatesSeekingAlpha
Jun-10-26
Jun-10-2612:02AM
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue7100——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit7100——————
Selling, General and Administrative Excl. Other956195——————
Research and Development339238160——————
Other Operating Expense
000——————
Operating Income-363-299-254——————
Interest Expense532——————
Unusual Expense
—————————
Non-Operating Income (Expense)263219——————
Net Income Before Taxes-343-270-238——————
Income Taxes
000——————
Consolidated Net Income-343-270-238——————
Net Income From Continuing Operations-343-270-238——————
Net Income-343-270-238——————
EPS (Recurring)-3.32-3.98-5.31——————
EPS (Basic, Before Extraordinaries)-3.32-3.98-5.31——————
EPS (Diluted)-3.32-3.98-5.31——————
EBITDA-337-266-235——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio37.26————————
Gross Margin100.00————————
Operating Margin-511.27————————
Net Margin-483.10————————
Shares Outstanding856845——————
Market Capitalization2,6451,304980——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$36.85$30.20$23.54$16.88$10.23● Close Price0.00M5.00M10.00M15.00M20.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fairmount Funds Management LLCdirector, 10 percent owner:May 11 '26Buy17.001,176,47019,999,9905,090,928May 13
Mahoney Stephen F.President and CEOMar 03 '26Option Exercise0.0018,357040,757Mar 04
Tousignant JenniferChief Legal OfficerMar 03 '26Option Exercise0.005,16905,169Mar 04
Beetham Thomas W.Chief Operating OfficerMar 03 '26Option Exercise0.009,409016,409Mar 04
Harmon SethChief Financial OfficerMar 03 '26Option Exercise0.006,26709,881Mar 04
Tousignant JenniferChief Legal OfficerDec 31 '25Sale31.162,27270,7960Jan 02
Fairmount Funds Management LLCdirector, 10 percent owner:Oct 23 '25Buy22.00454,5459,999,9903,914,458Oct 27
Fairmount Funds Management LLCdirector, 10 percent owner:Jun 10 '25Option Exercise12.3112,500153,8753,459,913Jun 11
Fairmount Funds Management LLCdirector, 10 percent owner:Jun 09 '25Option Exercise7.801,60012,4803,447,413Jun 11
Beetham Thomas W.Chief Operating OfficerSep 27 '24Buy23.415,000117,0506,000Sep 30
Mahoney Stephen F.President and CEOSep 27 '24Buy23.3321,400499,26221,400Sep 30
Fairmount Funds Management LLCdirector, 10 percent owner:Sep 13 '24Buy18.751,600,00030,000,0003,445,813Sep 17
Fairmount Funds Management LLCdirector, 10 percent owner, other: See RemarksJan 22 '24Buy21.00476,1909,999,9901,839,954Jan 24
Meisner LaraChief Legal OfficerJun 16 '23Option Exercise23.03551,26737,453Jun 20
Meisner LaraChief Legal OfficerJun 16 '23Sale28.352776529,971Jun 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.